CD79A and inflammatory bowel disease: Further delineation of the specific factors, which initiate and maintain intestinal IgG+ plasma cell niches, could enable therapeutic targeting to disrupt the production of pathogenic IgG+ in IBD whilst sparing beneficial homeostatic IgA‐producing cells.